BDPT BIOADAPTIVES, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1575142 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY230.2%
TTM net income YoY-106.3%
TTM EPS YoY—
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin-3,610.9%
Net margin-8,805.9%
FCF margin—
EBITDA margin-3,587.7%
Returns
ROE—
ROA-2,510.3%
ROIC (approx.)—
Asset turnover0.29x
Leverage & solvency
Liabilities / assets4,703.4%
Debt / equity—
Current ratio0.02x
Interest coverage-2.42x
Cash quality & payout
Operating cash flow / net income0.17x
Accruals ratio-2,071.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $18,278 | $12,669 |
| Cost of revenue | $5,781 | $8,639 |
| Gross profit | $12,497 | $4,030 |
| SG&A expense | $820,508 | $335,306 |
| Operating income | -$1.04M | -$602,090 |
| Interest expense | $70,880 | $91,978 |
| Pretax income | -$1.56M | -$899,161 |
| Income tax | $0 | $0 |
| Net income | -$1.56M | -$899,161 |
| EBITDA | -$1.04M | -$602,090 |
| EPS (basic) | — | -0.11 |
| EPS (diluted) | -0.15 | -0.11 |
| Weighted avg. shares (diluted) | 10.07M | 8.22M |
| Balance sheet | ||
| Cash & equivalents | $158,445 | $137,470 |
| Short-term investments | $0 | $0 |
| Inventory | $44,706 | $19,115 |
| Current assets | $211,901 | $261,885 |
| PP&E, net | $14,000 | $0 |
| Intangibles | $14,000 | $0 |
| Total assets | $225,901 | $261,885 |
| Current liabilities | $2.36M | $1.73M |
| Total liabilities | $2.36M | $1.73M |
| Shareholders' equity | -$2.13M | -$1.46M |
| Shares outstanding | 12.01M | 8.22M |
| Cash flow statement | ||
| Operating cash flow | -$516,025 | -$249,517 |
| Capital expenditure | $18,000 | $0 |
| Free cash flow | -$534,025 | -$249,517 |
| Investing cash flow | -$18,000 | $0 |
| Financing cash flow | $555,000 | $326,211 |
| Depreciation & amortization | $4,000 | $0 |
| Stock-based compensation | $28,670 | — |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.